1
|
Hou X, Guan Y, He S, Wu Z, Bai J, Xu J, Wang J, Xu S, Zhu H, Yin Y, Yang X, Shi Y. A novel self-assembled nanoplatform based on retrofitting poloxamer 188 for triple-negative breast cancer targeting treatment. Chem Biol Interact 2023; 384:110710. [PMID: 37716421 DOI: 10.1016/j.cbi.2023.110710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Revised: 09/01/2023] [Accepted: 09/11/2023] [Indexed: 09/18/2023]
Abstract
Poloxamer 188 is a widely used pharmaceutical excipient, which can be found in a variety of drug formulations. In this study, a novel self-assembled nanoplatform was developed for active targeting of folate receptor-overexpressing triple-negative breast cancer. This platform, FPP NPs, was prepared by the retrofitted poloxamer 188 derivatives, resulting in nanoparticles with an appropriate size (< 100 nm), good stability, and satisfactory biocompatibility. Cellular uptake and in vivo distribution studies showed that the FPP NPs had strong tumor cell uptake and active targeting capabilities. Furthermore, docetaxel (DTX) was loaded into FPP NPs in this research. The resulting DTX/FPP NPs exhibited high drug encapsulation efficiency and drug loading capacity, and could rapidly release DTX under slightly acidic conditions, significantly increasing the antitumor activity of the encapsulated drug both in vitro and in vivo. In addition, DTX/FPP NPs could significantly decrease the hepatotoxicity and nephrotoxicity of DTX. Therefore, this drug delivery nanoplatform, based on retrofitted poloxamer 188 with self-assembly properties in aqueous solution and active targeting capabilities to tumors, may provide a promising approach for targeted treatment of triple-negative breast cancer.
Collapse
Affiliation(s)
- Xueyan Hou
- School of Pharmacy, Xinxiang Medical University, Henan, 453003, PR China.
| | - Yalin Guan
- School of Pharmacy, Xinxiang Medical University, Henan, 453003, PR China
| | - Sisi He
- Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Guizhou, 563000, PR China
| | - Zeqing Wu
- School of Pharmacy, Xinxiang Medical University, Henan, 453003, PR China
| | - Jintao Bai
- School of Pharmacy, Xinxiang Medical University, Henan, 453003, PR China
| | - Jingjing Xu
- School of Pharmacy, Xinxiang Medical University, Henan, 453003, PR China
| | - Jingwen Wang
- School of Pharmacy, Xinxiang Medical University, Henan, 453003, PR China
| | - Suyue Xu
- School of Pharmacy, Xinxiang Medical University, Henan, 453003, PR China
| | - Huiqing Zhu
- School of Pharmacy, Xinxiang Medical University, Henan, 453003, PR China
| | - Yanyan Yin
- School of Pharmacy, Xinxiang Medical University, Henan, 453003, PR China
| | - Xue Yang
- School of Pharmacy, Xinxiang Medical University, Henan, 453003, PR China.
| | - Yongli Shi
- School of Pharmacy, Xinxiang Medical University, Henan, 453003, PR China.
| |
Collapse
|
2
|
Negut I, Bita B. Polymeric Micellar Systems-A Special Emphasis on "Smart" Drug Delivery. Pharmaceutics 2023; 15:pharmaceutics15030976. [PMID: 36986837 PMCID: PMC10056703 DOI: 10.3390/pharmaceutics15030976] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 03/13/2023] [Accepted: 03/15/2023] [Indexed: 03/30/2023] Open
Abstract
Concurrent developments in anticancer nanotechnological treatments have been observed as the burden of cancer increases every year. The 21st century has seen a transformation in the study of medicine thanks to the advancement in the field of material science and nanomedicine. Improved drug delivery systems with proven efficacy and fewer side effects have been made possible. Nanoformulations with varied functions are being created using lipids, polymers, and inorganic and peptide-based nanomedicines. Therefore, thorough knowledge of these intelligent nanomedicines is crucial for developing very promising drug delivery systems. Polymeric micelles are often simple to make and have high solubilization characteristics; as a result, they seem to be a promising alternative to other nanosystems. Even though recent studies have provided an overview of polymeric micelles, here we included a discussion on the "intelligent" drug delivery from these systems. We also summarized the state-of-the-art and the most recent developments of polymeric micellar systems with respect to cancer treatments. Additionally, we gave significant attention to the clinical translation potential of polymeric micellar systems in the treatment of various cancers.
Collapse
Affiliation(s)
- Irina Negut
- National Institute for Laser, Plasma and Radiation Physics, 409 Atomistilor Street, Magurele, 077125 Bucharest, Romania
| | - Bogdan Bita
- National Institute for Laser, Plasma and Radiation Physics, 409 Atomistilor Street, Magurele, 077125 Bucharest, Romania
- Faculty of Physics, University of Bucharest, 077125 Măgurele, Romania
| |
Collapse
|
3
|
Wu Y, Wang M, Li Y, Xia H, Cheng Y, Liu C, Xia Y, Wang Y, Yue Y, Cheng X, Xie Z. The Fabrication of Docetaxel-Containing Emulsion for Drug Release Kinetics and Lipid Peroxidation. Pharmaceutics 2022; 14:pharmaceutics14101993. [PMID: 36297429 PMCID: PMC9607308 DOI: 10.3390/pharmaceutics14101993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Revised: 09/16/2022] [Accepted: 09/17/2022] [Indexed: 11/19/2022] Open
Abstract
Docetaxel (DTX)-based formulation development is still confronted with significant challenges, due to its refractory solubility and side effects on normal tissues. Inspired by the application of the transdermal drug delivery model to topical treatment, we developed a biocompatible and slow-release DTX-containing emulsion via self-assembly prepared by a high-speed electric stirring method and optimized the formulation. The results of accelerated the emulsion stability experiment showed that the emulsion prepared at 10,000 rpm/min had a stability of 89.15 ± 2.05%. The ADME, skin irritation, skin toxicity and molecular interaction between DTX and excipients were predicted via Discovery Studio 2016 software. In addition, DTX addition in oil or water phases of the emulsion showed different release rates in vitro and ex vivo. The DTX release ex vivo of the DTX/O-containing emulsion and the DTX/W-containing emulsion were 45.07 ± 5.41% and 96.48 ± 4.54%, respectively. In vitro antioxidant assays and anti-lipid peroxidation models revealed the antioxidant potential of DTX. However, DTX-containing emulsions could maintain and even enhance the antioxidant effect, both scavenging free radicals in vitro and inhibiting the process of lipid peroxidation.
Collapse
Affiliation(s)
- Yifang Wu
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
| | - Mengmeng Wang
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
| | - Yufan Li
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
| | - Hongmei Xia
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
- Correspondence: (H.X.); (Y.C.); Tel./Fax: +86-13965033210 (H.X.)
| | - Yongfeng Cheng
- Clinical College of Anhui Medical University, Hefei 230601, China
- School of Life Science, University of Science and Technology of China, Hefei 230027, China
- Correspondence: (H.X.); (Y.C.); Tel./Fax: +86-13965033210 (H.X.)
| | - Chang Liu
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
| | - Ying Xia
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
| | - Yu Wang
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
| | - Yan Yue
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
| | - Xiaoman Cheng
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
| | - Zili Xie
- Anhui Institute for Food and Drug Control, Hefei 230051, China
| |
Collapse
|